Anellovirus genome quantification as a biomarker of immune suppression
US10144975B2 · kind B2 · utility
0Cited by
0References
45Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 19, 2013 |
| Grant date | Dec 4, 2018 |
| Priority date | — |
| Expiry date | Nov 30, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.